title: Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.
authors.affiliation: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
authors.forename: Stuart A
authors.initials: SA
authors.lastname: Grossman
authors.affiliation: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
authors.forename: Karisa C
authors.initials: KC
authors.lastname: Schreck
authors.affiliation: Weill Cornell Medical College, New York, USA.
authors.forename: Karla
authors.initials: K
authors.lastname: Ballman
authors.affiliation: Dana Farber Cancer Institute, Boston, Massachusetts, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Alexander
mesh_terms: D001932:Brain Neoplasms / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D003606:Dacarbazine / Q000627:therapeutic use*; D005909:Glioblastoma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D003606:Dacarbazine
keywords: clinical trials; newly diagnosed glioblastoma; phase II; randomized; single-arm